Skip to main content
. Author manuscript; available in PMC: 2008 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2007 Dec;13(12):1499–1507. doi: 10.1016/j.bbmt.2007.09.004

Figure 1. Non-relapse mortality, relapse or progression, and overall survival according to donor type.

Figure 1

Cumulative incidence of non-relapse mortality (A) and relapse or progression (B), and Kaplan-Meier survival estimates (C) among patients with HLA-identical sibling donors (“MRD”, n=221) compared to those with HLA-matched unrelated donors (“URD”, n=184) (p=0.08). The third curve in each panel (“URD adjusted”) shows the projected survival with HLA-matched unrelated donors after adjusting for HCT-comorbidity index, relapse risk category, patient age, stem cell source, prior cytomegalovirus infection and donor/recipient sex-mismatch.